US FDA OKs Cadila Healthcare topicals plant
Cadila Healthcare Limited says its topical drug manufacturing plant has passed an inspection by the US Food and Drug Administration (FDA).
According to a Bombay Stock Exchange (BSE) filing, the Cadila plant in Changodar in Ahmedabad passed an inspection conducted by the US regulator last week with no Form 483 observations.
The facility manufacturers 17 generic topical pharmaceutical products for the US market according to Cadila.
